Yetrib Hathout joined the School of Pharmacy and Pharmaceutical Science of Binghamton University in January 2017. Previously, he was a tenured associated professor at Children’s National Health System and the George Washington University School of Medicine in Washington, D.C.
Hathout is a highly published, cited and funded authority in proteomics studies applied to biomedical sciences and biomarker development. He directed proteomic and biomarker cores for multiple National Institutes of Health Center grants and program projects while at Children’s National Medical Center. At the Binghamton School Pharmacy and Pharmaceutical Sciences, he continues working on transitioning biomarkers from bench to bedside for Duchenne muscular dystrophy and other neuromuscular diseases. Hathout also joined the Tick-borne Disease Research Center at Binghamton to implement proteomics technologies and develop diagnostic and prognostic biomarkers for Lyme disease.
His laboratory in the Department of Pharmaceutical Sciences at Binghamton University focuses on developing and standardising innovative mass spectrometry and proteomics methods for biomarker studies and for understanding the molecular mechanism of diseases. The goal is to define non-invasive serum and urine biomarkers to monitor disease progression and response to therapies for certain diseases, and also to develop novel therapeutic targets for incurable diseases such as neuromuscular diseases and cancer.
An analytical chemist by training, Hathout has worked throughout his career to advance the fields of clinical and translational research using mass spectrometry and proteomic methods. He has published more than 80 peer-reviewed articles in the field of proteomics and mass spectrometry applications. His complete list of publications can be found online. http://www.ncbi.nlm.nih.gov/pubmed/?term=hathout+y
- MS, University of Burgundy
- PhD, University of Burgundy
- Bio-analytical mass spectrometry
- Proteomic studies of human diseases